Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Circe Biomedical Inc.

Latest From Circe Biomedical Inc.

Start-Up News October 2006

Arbios Systems and Livercyte provide assistance for the failing liver, and Aperon Biosystems takes up the asthma challenge.
BioPharmaceutical Medical Device

Liver Roll-Ups? (Not the Deli Kind)

Merchant bank The Aethena Group aims to provide a new kind of resource to emerging and middle market companies that need a boost to get to a valuation level that supports investment by traditional investors. One field in need of such support, Aethena believes, is liver disease, which represents enormous untapped markets, but product risk associated with an evolving understanding of liver biology. Aethena hopes to offer strategic options to companies in this industry.
Medical Device Business Strategies

Algenix Inc.

Hoping to succeed where other liver assist devices have failed, Algenix Inc. aims to create, in an extracorporeal device, a microenvironment where hepatocytes retain a high degree of multifunctionality.
BioPharmaceutical Medical Device

Liver Assist Devices: Proof of Life

Apart from transplantation, until very recently, there have been no life-saving therapies available for liver failure. Now, one first-generation liver assist device is on the market and others are progressing through both biologic and device clinical trials. Companies with liver assist devices sort into two main groups: companies with dialysis and ultrafiltration systems that improve upon kidney dialysis and fall squarely on the device side of the divide for regulatory purposes, and those that incorporate living cells in a device-biologic combination, which require drug-like approvals. Regardless of the approval process, all companies need compelling efficacy data to convince clinicians and payers of the benefits of a brand new therapy. But the large numbers of variables and unknowns concerning liver function and liver disease have posed considerable obstacles to designing prospective, randomized, controlled clinical trials-a problem highlighted by Circe Biomedical's halting of its large Phase II/III clinical trial for lack of efficacy. There is no question that there is a tremendous need for liver support. What is tantalizing for both companies and investors in this area is that they feel liver assist devices do work-the liver can recover, physiological functions improve, patients with a prognosis of death have survived. But they just haven't been able to prove it yet, not in terms of the only endpoint that really counts at this early stage in the field, improvements in 30-day survival rates.
Medical Device Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Circe Biomedical Inc.
  • Senior Management
  • Barry A Solomon, Pres.
  • Contact Info
  • Circe Biomedical Inc.
    Phone: (781) 863-8720
    99 Hayden Ave.
    Lexington, MA 02421
    USA
UsernamePublicRestriction

Register